Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
Overview
Orthopedia (KIDS) is a specialized medical device company dedicated exclusively to the field of pediatric orthopedics. Operating at the intersection of advanced medical technology and clinical expertise, the company designs, develops, and commercializes anatomically appropriate implants and surgical instruments. These innovative solutions are crafted to meet the distinct needs of pediatric patients, addressing conditions from long bone deformity correction and trauma management to spinal procedures and sports medicine. Keywords such as pediatric orthopedics, surgical implants, and clinical education reinforce the company’s technical focus from the very first introduction.
Core Business and Product Offering
At the heart of Orthopedia's operations lies a commitment to empowering pediatric orthopedic surgeons. The company’s product portfolio encompasses a range of state-of-the-art implants and instruments – each meticulously engineered to provide optimal treatment outcomes. Their offerings include specialized devices that aid in the correction of limb deformities, stabilization of fractures, and support for reconstructions, all designed with the care and precision that pediatric cases demand.
- Dedicated Research and Development: Orthopedia invests in continuous innovation, leveraging cutting-edge technology to refine implant design and improve surgical outcomes.
- Clinical and Educational Support: Beyond product development, the company emphasizes comprehensive clinical education and support programs that help surgeons stay updated on the latest procedures and applications.
- Comprehensive Product Range: From long bone deformity correction to trauma, spine care, and sports medicine, the company offers an integrated suite of solutions tailored for pediatric needs.
Market Position and Industry Significance
Orthopedia has positioned itself as a trusted name within the pediatric orthopedic market. With an unwavering focus on quality and innovation, the company has developed an expertise that ensures its products meet rigorous safety and efficacy standards. Its dedicated approach sets it apart from competitors who cover broader orthopedic applications, as Orthopedia champions solutions specifically designed for children. This clear specialization has cemented its role as a key industry resource for surgeons looking for products that reliably address pediatric orthopaedic conditions.
Operational Excellence and Expertise
The company’s operational framework is built upon a solid foundation of expert knowledge and technical prowess. By integrating engineering innovation with clinical insight, Orthopedia ensures that every implant and instrument is both practical in a surgical environment and tailored for the unique demands of pediatric physiology. The emphasis on quality, reliability, and educational support further demonstrates a commitment to elevating standard practices within the field. This multifaceted approach underlines the company’s role as not only a supplier of medical devices, but also as a partner in advancing pediatric orthopedic care globally.
Customer and Stakeholder Focus
Orthopedia’s offerings are crafted with the end-user in mind, primarily targeting healthcare institutions and pediatric orthopedic surgeons. The company’s comprehensive support system includes detailed training and ongoing clinical education, ensuring that surgeons are capable of utilizing these advanced tools to their fullest potential. Through its balanced approach to innovation and education, Orthopedia helps customers achieve better surgical outcomes and improved quality of life for pediatric patients.
Conclusion
In summary, Orthopedia (KIDS) exemplifies an unwavering focus on the niche field of pediatric orthopedics. The company combines advanced product engineering, dedicated clinical support, and a targeted market strategy to address the specialized needs of pediatric surgical care. By maintaining a consistent emphasis on quality and clinical expertise, Orthopedia continues to serve as a central resource for pediatric orthopedic solutions in the healthcare industry.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced preliminary unaudited revenue for Q4 and full year 2021. Q4 revenue is estimated at $24.8 million, a 31% increase from Q4 2020's $18.9 million. Domestic revenue rose 11%, while international revenue surged 363%. Full year 2021 revenue is expected to reach $98.0 million, reflecting 38% growth. Domestic sales grew 24%, and international sales increased 150%. The final financial results will be released in March 2022, as these figures are subject to audit adjustments.
Telos Partners LLC, a subsidiary of OrthoPediatrics Corporation (NASDAQ: KIDS), has appointed Scott Day as Senior VP and General Manager. This follows the leadership of Jason Inzana, who established a strong foundation for predictable revenue. Since the acquisition, Telos has doubled its team and expanded its client base, positioning itself for growth amid industry challenges. Day, with a successful track record in medical technology, aims to lead Telos through an aggressive growth phase while ensuring high-quality outcomes for clients.
OrthoPediatrics Corp. (NASDAQ: KIDS) recently reaffirmed its commitment as a Double-Diamond sponsor of the International Pediatric Orthopaedic Symposium (IPOS) held from December 7 to 11 in Orlando, Florida, attracting over 400 pediatric orthopedic surgeons. CEO David Bailey emphasized the value of in-person connections and the company's enduring partnership with the Pediatric Orthopedic Society of North America (POSNA). Furthermore, OrthoPediatrics showcased its expanding portfolio, including exclusive technologies like ApiFix and 7D Flash Intraoperative Navigation, aimed at enhancing pediatric orthopedic practices.
OrthoPediatrics Corp (Nasdaq: KIDS) announced its participation in the 33rd Annual Piper Sandler Virtual Healthcare Conference with a fireside chat webcast featuring CEO Dave Bailey and COO Fred Hite. This event will include 1x1 investor meetings scheduled for December 1, 2021, accessible exclusively through Piper Sandler. Additionally, the audio webcast will be available on OrthoPediatrics' investor relations website until December 2, 2021. OrthoPediatrics specializes in pediatric orthopedics, offering 36 surgical systems to enhance care for children with orthopedic conditions.
OrthoPediatrics Corp. (KIDS) reported a third quarter 2021 revenue of $25.1 million, a 13% increase from $22.2 million in Q3 2020. Domestic revenue fell 1% to $19.4 million, while international revenue surged 118% to $5.7 million. Trauma and Deformity revenue was up 12%, Scoliosis revenue grew 11%, and Sports Medicine/Other revenue rose 46%. The company maintained its full-year revenue guidance of $97-$101 million, projecting 36% to 42% growth over 2020. Net loss narrowed to $2.2 million from $4.5 million year-on-year.
OrthoPediatrics Corp (Nasdaq: KIDS) will have key executives participating in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 10:00 AM ET. The executives include President & CEO Dave Bailey, COO and CFO Fred Hite, and Executive Chairman Mark Throdahl. The event will feature a webcast format and include one-on-one meetings. An audio replay of the presentation will be made available for 90 days on the company's investor relations website, showcasing their dedicated focus on pediatric orthopedic advancements.
OrthoPediatrics Corp. (KIDS) has received a Silver metal designation in the "COVID Stops Here" campaign for achieving an 80%+ vaccination rate at its Indiana headquarters. This recognition highlights the importance of widespread vaccinations in combatting COVID-19, particularly the Delta variant. OrthoPediatrics' President emphasized the company's commitment to the health and safety of its employees throughout the pandemic. The campaign, promoted by the Indiana Chamber of Commerce, aims to encourage more organizations to prioritize COVID-19 vaccinations.
OrthoPediatrics Corp. (KIDS) has announced preliminary third quarter 2021 revenue of approximately $25.1 million, a 13% increase from $22.2 million in the same period last year. However, the revenue was impacted by increased COVID-19 Delta variant cases and RSV cases affecting children's hospitals along with hospital staff shortages. The company maintains its 2021 total revenue guidance of $97 million to $101 million. These figures are preliminary and subject to audit adjustments.
A conference call is scheduled for November 4, 2021.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its Platinum-level sponsorship for the AACPDM Annual Meeting, occurring virtually from October 6-9, 2021. The company will provide scholarships, educational support, and showcase products at the event. OrthoPediatrics emphasizes its commitment to pediatric orthopedic education, having recently participated in the Scoliosis Research Society meeting and the POST Course, which trains orthopedic residents in pediatric surgical techniques. President David Bailey highlighted the positive impact of their educational support in advancing the field.
OrthoPediatrics Corp. (Nasdaq: KIDS) has announced a 5-year exclusive distribution agreement with SeaSpine Orthopedics to distribute the 7D Surgical FLASH™ Navigation platform for pediatric applications. This agreement allows OrthoPediatrics to enhance surgical workflows and patient safety in pediatric orthopedic surgeries by utilizing radiation-free technology. The FLASH Navigation system, featuring innovative camera-based technology, eliminates the need for intra-operative CT and fluoroscopy, significantly reducing radiation exposure. This partnership aligns with OrthoPediatrics' commitment to pediatric orthopedics and innovation.